2003•PubMedRequires access

[Clinical analysis of 282 patients with non-Hodgkin's lymphoma].

Shuping Chen, Dengshu Wu, Xielan Zhao

Open publisher page 0 citations

Abstract

OBJECTIVE: To analyze the classification, stage and prognosis of non-Hodgkin's lymphoma (NHL). METHODS: Two hundred eighty two patients with NHL were retrospectively reviewed. RESULTS: The complete remission (CR) rate and 5-year survival rate of B-cell NHL were higher than those of T-cell NHL(P < 0.05). There were significant differences in CR rate and 5-year survival rate among the low-grade, the intermediate-grade and the high-grade NHL(P < 0.05). The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05). CONCLUSION: Rational classification and staging play an important role in the prognosis of NHL. CHOP-based scheme may be regarded as the first choice and the standard scheme of treatment.

About this research paper

What this paper is about

OBJECTIVE: To analyze the classification, stage and prognosis of non-Hodgkin's lymphoma (NHL). METHODS: Two hundred eighty two patients with NHL were retrospectively reviewed. RESULTS: The complete remission (CR) rate and 5-year survival rate of B-cell NHL were higher than those of T-cell NHL(P < 0.05). There were significant differences in CR rate and 5-year survival rate among the low-grade, the intermediate-grade and the high-grade NHL(P < 0.05). The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05). CONCLUSION: Rational classification and staging play an important role in the prognosis of NHL. CHOP-based scheme may be regarded as the first choice and the standard scheme of treatment.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: To analyze the classification, stage and prognosis of non-Hodgkin's lymphoma (NHL). METHODS: Two hundred eighty two patients with NHL were retrospectively reviewed. RESULTS: The complete remission (CR) rate and 5-year survival rate of B-cell NHL were higher than those of T-cell NHL(P < 0.05). There were significant differences in CR rate and 5-year survival rate among the low-grade, the intermediate-grade and the high-grade NHL(P < 0.05). The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05). CONCLUSION: Rational classification and staging play an important role in the prognosis of NHL. CHOP-based scheme may be regarded as the first choice and the standard scheme of treatment.

Key concepts: Vincristine, Prednisone, Etoposide, Medicine, CHOP, Cyclophosphamide, Internal medicine, Lymphoma

Related papers

Back to paper searchBrowse research topicsOriginal source
[Clinical analysis of 282 patients with non-Hodgkin's lymphoma]. — Research Paper | ScholarLens